Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Stock Market Falls On Soaring Oil Prices, Yields, But Finishes Strong; CPI Inflation, Apple, Oracle, Meta In Focus: Weekly Review